Cicletanine for the treatment of pulmonary arterial hypertension

Archives of Internal Medicine

Volumn 168, Issue 19, 2008, Pages 2164-2166

  Waxman, Aaron B ^a   Lawler, Laurie ^b   Cornett, Glenn ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CICLETANINE; FUROSEMIDE; NITRIC OXIDE; SILDENAFIL; SITAXSENTAN; SPIRONOLACTONE; TADALAFIL; UNIPROST;

ADULT; ARTICLE; CASE REPORT; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FUNCTION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; FATAL OUTCOME; FEMALE; HUMANS; HYPERTENSION, PULMONARY; PYRIDINES;

EID: 54949091985     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.19.2164     Document Type: Article

References (19)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002-2012.
2. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269(19):13725-13728.
3. Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis. 1995;38(2):105-128.
4. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159-165.
5. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol. 2005;100(3):347-353.
6. Ferdinand KC. African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans. Am J Cardiol. 2007;99(6B)(suppl):3D-6D.
7. Lapu-Bula R, Ofili E. From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography. Am J Cardiol. 2007;99(6B)(suppl):7D-14D.
8. Kakar P, Lip GY. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther. 2007;5(3):441-450.
9. Akamatsu N, Sawada S, Komatsu S, et al. Effect of cicletanine on the nitric oxide pathway in human umbilical vein endothelial cells. J Cardiovasc Pharmacol. 2001;38(2):174-182.
10. Kalinowski L, Dobrucki IT, Malinski T. Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells. J Cardiovasc Pharmacol. 2001;37(6):713-724.
11. Szilvássy Z, Csont T, Pali T, Droy-Lefaix MT, Ferdinandy P. Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine. J Vasc Res. 2001;38(1):39-46.
12. Chamiot-Clerc P, Choukri N, Legrand M, Droy-Lefaix MT, Safar ME, Renaud JF. Relaxation of vascular smooth muscle by cicletanine in aged Wistar aorta under stress conditions: importance of nitric oxide. Am J Hypertens. 2000;13(2):208-213.
13. Hirawa N, Uehara Y, Kawabata Y, et al. Restoration of endothelial cell function by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension. Hypertens Res. 1996;19(4):263-270.
14. Tarrade T, Guinot P. Efficacy and tolerance of cicletanine, a new antihypertensive agent: overview of 1226 treated patients. Drugs Exp Clin Res. 1988;14(2-3):205-214.
15. Saadjian A, Philip-Joet F, Paganelli F, Arnaud A, Levy S. Long-term effects of cicletanine on secondary pulmonary hypertension. J Cardiovasc Pharmacol. 1998;31(3):364-371.
16. Montalescot G, Maclouf J, Drobinski G, Grosgogeat Y, Thomas D, Morin E. Cicletanine lowers pulmonary arterial resistance in patients with severe heart failure and pulmonary hypertension. In: Abstract book from the VI World Conference on Clinical Pharmacology and Therapeutics (IUPHAR); August 4-9, 1996; Buenos Aires, Argentina. Abstract 272.
17. Malherbe E, Le Hegarat M, Clostre F, Braquet P. Comparison of cicletanine with other antihypertensive drugs in SHR-SP models. Drugs Exp Clin Res. 1988;14(2-3):83-88.
18. Burton T, Chakrabarty S, Fluck DS, Flores NA, Sheridan DJ. Effects of cicletanine on haemodynamics, arrhythmias and extent of necrosis during coronary ligation in rabbits. Br J Pharmacol. 1992;107(4):1135-1139.
19. Ferdinandy P, Szilvassy Z, Csont T, Koltai M, Droy-lefaix MT. Cardioprotective effect of enantiomers of cicletanine (BN50417, BN50418) in ischaemic/ reperfused isolated working rat hearts: interaction with glibenclamide. Pharmacol Res. 1999;39(3):225-231.